France· FR:68671625
BRAFTOVI 50 mg, gélule
A medicinal product containing encorafénib, registered in France by PIERRE FABRE MEDICAMENT, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ENCORAFÉNIB
- Manufacturer
- PIERRE FABRE MEDICAMENT
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009301568417 plaquette(s) polyamide aluminium PVC de 4 gélule(s)EUR 580.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Encorafénib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRAFTOVIPIERRE FABRE MEDICAMENT, Lavaur
- SwitzerlandBraftovi
- FinlandBraftoviPierre Fabre Medicament
- United KingdomBraftovi 50mg capsulesPierre Fabre Ltd
- IrelandBraftovi 50 mg Hard capsulePierre Fabre Medicament
- IcelandBraftoviPierre Fabre Medicament
- NetherlandsBraftovi 50 mg capsule, hardPierre Fabre Medicament
- NorwayBraftoviPierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Braftovi
- Liechtenstein · Braftovi
- Norway · Braftovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f5f04265-5f66-4eb5-a30a-52174a4bdfa1 GET /v1/drugs/f5f04265-5f66-4eb5-a30a-52174a4bdfa1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68671625",
"date_amm": "2018-09-20",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1314",
"substance": "ENCORAFÉNIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about encorafénib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.